EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers

Young Su Joo iD, Tae-Ik Chang iD, Dong Ki Kim iD, Seung Hyeok Han iD, Shin-Wook Kang, Tae-Hyun Yoo iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfaf187 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Young Su Joo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Calcitriol, Proteinuria, Renin-Angiotensin System. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Hanmi Pharmaceutical, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with immunoglobulin A nephropathy (IgAN) and moderate proteinuria are at risk of progressive renal failure despite the maximal use of renin–angiotensin system blockers (RASBs). This study evaluated the efficacy of active vitamin D in reducing proteinuria in patients with IgAN receiving RASBs.

Methods

In this double-blind, placebo-controlled trial, we enrolled biopsy-confirmed patients with IgAN and persistent proteinuria (0.5–3.5 g/day) after maximal use of RASBs. Patients were randomized to receive either 0.25 μg/day of calcitriol or placebo for 12 months. The primary outcomes were the change in the mean urinary protein:creatinine ratio (UPCR) and daily urinary protein excretion during the treatment.

Results

A total of 138 patients from six medical centres were enrolled and assigned to receive a placebo (n = 69) or 0.25 μg of calcitriol (n = 69) and 115 patients (83.3%) completed the study. The calcitriol group showed a greater reduction in geometric means of UPCR {mean difference −187 mg/g [95% confidence interval (CI) −370.6 to −4.0], P = .04} and urinary albumin:creatinine ratio [−162 mg/g (95% CI −290.9 to −34.6), P = .01] than placebo. Changes in daily urinary protein excretion were −3.5% (from 1.32 to 1.02 g/day) in the control group and −13.1% (from 1.29 to 0.97 g/day) in the calcitriol group, without any statistically significant differences (P = .11). The annual decrease of the estimated glomerular filtration rate (eGFR) was −0.32 ml/min/1.73 m2 (95% CI −2.54 to 1.99) in the calcitriol group and −3.64 ml/min/1.73 m2 (95% CI −5.70 to −1.58) in the placebo group (calcitriol versus placebo over time, P = .02). Adverse events were comparable between the groups.

Conclusion

The addition of 0.25 μg/day calcitriol to RASBs safely lowered residual proteinuria and slowed the eGFR decline in patients with IgAN, suggesting a potential therapeutic role for calcitriol in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGACalcitriolProteinuriaRenin-Angiotensin SystemAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsHumansMaleFemaleDouble-Blind MethodAdultGlomerular Filtration RateAdministration, OralMiddle AgedFollow-Up StudiesPrognosisKidney Function Tests

Stichwörter der Autor:innen

IgA nephropathycalcitriolimmunoglobulin A nephropathyvitamin D

Substanzen

CalcitriolAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea.
  • Division of Nephrology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea.
  • Department of Internal Medicine, National Health Insurance Service Medical Center, Ilsan Hospital, Goyang, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

ORCID-Profile: Young Su Joo, Tae-Ik Chang, Dong Ki Kim, Seung Hyeok Han, Tae-Hyun Yoo

Förderung

  • Hanmi Pharmaceutical, Seoul, Korea

Zitieren

APA

Joo, Y. S., Chang, T. I., Kim, D. K., Han, S. H., Kang, S. W., & Yoo, T. H. (2026). Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf187

Vancouver

Joo YS, Chang TI, Kim DK, Han SH, Kang SW, Yoo TH. Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf187

BibTeX
@article{Joo2026,
  author = {Joo, Young Su and Chang, Tae-Ik and Kim, Dong Ki and Han, Seung Hyeok and Kang, Shin-Wook and Yoo, Tae-Hyun},
  title = {Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfaf187}
}
Kostenlos starten →